Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate (Q34550827)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate |
scientific article |
Statements
1 reference
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate (English)
1 reference
Caio M Rocha Lima
1 reference
Mark R Green
1 reference
Robert Rotche
1 reference
Wilson H Miller
1 reference
G Mark Jeffrey
1 reference
Laura A Cisar
1 reference
Adele Morganti
1 reference
Nicoletta Orlando
1 reference
Gabriela Gruia
1 reference
Langdon L Miller
1 reference
1 September 2004
1 reference
1 reference
Identifiers
1 reference